ANI Pharmaceuticals Inc
ANIP64.425USD
+0.495+0.77%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.40BCap. mercado
PérdidaP/E TTM
Más Datos de ANI Pharmaceuticals Inc Compañía
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.
Información de la empresa
Símbolo de cotizaciónANIP
Nombre de la empresaANI Pharmaceuticals Inc
Fecha de salida a bolsaMay 04, 2000
Director ejecutivoMr. Nikhil Suresh Lalwani
Número de empleados897
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 04
Dirección210 Main Street West
CiudadBAUDETTE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal56623
Teléfono12186343500
Sitio Webhttps://www.anipharmaceuticals.com/
Símbolo de cotizaciónANIP
Fecha de salida a bolsaMay 04, 2000
Director ejecutivoMr. Nikhil Suresh Lalwani
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
468.18K
+5.44%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
89.90K
-0.97%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
79.05K
+5.80%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
64.66K
-4.24%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
55.86K
+8.42%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
45.02K
+35.72%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
26.96K
+19.17%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
16.33K
+36.15%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
468.18K
+5.44%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
89.90K
-0.97%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
79.05K
+5.80%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
64.66K
-4.24%
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Sales of generic pharmaceutical products
98.68M
0.00%
Sales of rare disease pharmaceutical products
52.85M
0.00%
Sales of Cortrophin Gel
52.85M
0.00%
Sales of branded pharmaceutical products
29.48M
0.00%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Sales of generic pharmaceutical products
98.68M
0.00%
Sales of rare disease pharmaceutical products
52.85M
0.00%
Sales of Cortrophin Gel
52.85M
0.00%
Sales of branded pharmaceutical products
29.48M
0.00%
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
5.44%
Meridian Venture Partners
5.38%
Millennium Management LLC
5.16%
Global Alpha Capital Management Ltd.
3.40%
Other
69.35%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
5.44%
Meridian Venture Partners
5.38%
Millennium Management LLC
5.16%
Global Alpha Capital Management Ltd.
3.40%
Other
69.35%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
41.99%
Investment Advisor/Hedge Fund
21.79%
Hedge Fund
20.04%
Research Firm
8.69%
Individual Investor
8.42%
Private Equity
5.38%
Corporation
2.94%
Bank and Trust
1.38%
Pension Fund
0.90%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
504
24.16M
111.60%
-1.18M
2025Q1
511
24.19M
111.77%
-1.42M
2024Q4
489
23.75M
109.53%
-1.38M
2024Q3
473
23.30M
110.79%
+2.44M
2024Q2
446
19.77M
94.29%
-402.06K
2024Q1
424
18.72M
89.20%
-877.00K
2023Q4
409
18.10M
88.69%
-881.29K
2023Q3
396
18.38M
91.57%
-127.77K
2023Q2
370
17.73M
90.91%
+852.82K
2023Q1
341
15.70M
87.63%
-1.26M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
2.44M
11.27%
-89.22K
-3.53%
Mar 31, 2025
The Vanguard Group, Inc.
1.18M
5.44%
-132.90K
-10.14%
Mar 31, 2025
Meridian Venture Partners
1.16M
5.38%
-255.00K
-17.97%
Mar 11, 2025
Millennium Management LLC
1.12M
5.16%
+298.32K
+36.45%
May 30, 2025
Global Alpha Capital Management Ltd.
735.59K
3.4%
+111.04K
+17.78%
Mar 31, 2025
Citadel Advisors LLC
723.33K
3.34%
+131.74K
+22.27%
Mar 31, 2025
State Street Global Advisors (US)
714.57K
3.3%
-22.72K
-3.08%
Mar 31, 2025
Deep Track Capital LP
700.00K
3.23%
+50.96K
+7.85%
Mar 31, 2025
Esjay L.L.C,
632.62K
2.92%
-200.00K
-24.02%
Mar 14, 2025
Dimensional Fund Advisors, L.P.
631.56K
2.92%
-54.17K
-7.90%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco Pharmaceuticals ETF
3.03%
SPDR S&P Pharmaceuticals ETF
2.41%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.71%
Invesco S&P SmallCap Health Care ETF
0.79%
iShares U.S. Pharmaceuticals ETF
0.56%
First Trust Small Cap Growth AlphaDEX Fund
0.54%
Invesco S&P SmallCap 600 Pure Growth ETF
0.46%
VictoryShares US Small Mid Cap Value Momentum ETF
0.38%
First Trust Small Cap Core Alphadex Fund
0.29%
First Trust Active Factor Small Cap ETF
0.24%
Ver más
Invesco Pharmaceuticals ETF
Proporción3.03%
SPDR S&P Pharmaceuticals ETF
Proporción2.41%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.71%
Invesco S&P SmallCap Health Care ETF
Proporción0.79%
iShares U.S. Pharmaceuticals ETF
Proporción0.56%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.54%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporción0.46%
VictoryShares US Small Mid Cap Value Momentum ETF
Proporción0.38%
First Trust Small Cap Core Alphadex Fund
Proporción0.29%
First Trust Active Factor Small Cap ETF
Proporción0.24%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
